Literature DB >> 16693604

The Effect of I.D.U. on Experimental and Clinical Herpes Simplex Infections.

R C Ey, W F Hughes, A W Holmes, F Deinhardt.   

Abstract

Year:  1963        PMID: 16693604      PMCID: PMC1316640     

Source DB:  PubMed          Journal:  Trans Am Ophthalmol Soc        ISSN: 0065-9533


× No keyword cloud information.
  8 in total

1.  A double-blind study of the effect of 5-iodo-2'-deoxyuridine on experimental herpes simplex keratitis.

Authors:  M E CORWIN; M OKUMOTO; P THYGESON; E JAWETZ
Journal:  Am J Ophthalmol       Date:  1963-02       Impact factor: 5.258

2.  The effectiveness of 5-iodo-2-deoxyuridine in the treatment of herpes simplex keratitis.

Authors:  F P FURGIUELE; G F PENTECOST; M KLEIN; J S McGAVIC
Journal:  Trans Am Ophthalmol Soc       Date:  1962

3.  Chemotherapy of herpes simplex keratitis.

Authors:  D M GORDON; D A KARNOFSKY
Journal:  Am J Ophthalmol       Date:  1963-02       Impact factor: 5.258

4.  IDU therapy of herpetic keratitis.

Authors:  W H HAVENER; J WACHTEL
Journal:  Am J Ophthalmol       Date:  1963-02       Impact factor: 5.258

5.  IDU therapy of herpes simplex.

Authors:  H E KAUFMAN; A B NESBURN; E D MALONEY
Journal:  Arch Ophthalmol       Date:  1962-05

6.  Anti-viral activities of several iodinated pyrimidine deoxyribonucleosides.

Authors:  E S PERKINS; R M WOOD; M L SEARS; W H PRUSOFF; A D WELCH
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

7.  Use of 5-iodo-2'-deoxyuridine (IDU) in treatment of herpes simplex keratitis.

Authors:  H KAUFMAN; E L MARTOLA; C DOHLMAN
Journal:  Arch Ophthalmol       Date:  1962-08

8.  Treatment of corneal disease with 5-iodo-2'-deoxyuridine (IDU). A clinical evaluation of 500 cases.

Authors:  E MAXWELL
Journal:  Am J Ophthalmol       Date:  1963-02       Impact factor: 5.258

  8 in total
  1 in total

1.  Experimental ulcerative herpetic keratitis. I. Systemic immune responses and resistance to corneal infection.

Authors:  C Carter; D L Easty
Journal:  Br J Ophthalmol       Date:  1981-02       Impact factor: 4.638

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.